Ascletis Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Ascletis Pharma (HKG:1672) Full Year 2023 Results
Key Financial Results
- Net loss: CN¥144.7m (loss narrowed by 54% from FY 2022).
- CN¥0.14 loss per share (improved from CN¥0.29 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ascletis Pharma Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) missed analyst estimates by 13%.
Looking ahead, revenue is expected to decline by 22% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Hong Kong are expected to grow by 25%.
Performance of the Hong Kong Biotechs industry.
The company's shares are down 6.3% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Ascletis Pharma has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:1672
Ascletis Pharma
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
Flawless balance sheet very low.
